Funding·October 23, 2026 at 8:00 AM EDT·4 sources
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
raise, log scale$237M
$100M$1B$10B$100B
What happened
- Pathos AI raised $237 million in a Series E round at a $3 billion post-money valuation.
- The round values Pathos above its $1.6 billion valuation in May 2025.
- The deal brings together Tempus’ dataset, Pathos’ AI analysis and drug development from BMS.
Series E raised
$237 million
Post-money valuation
$3 billion
May 2025 valuation
$1.6 billion
Why it matters
The financing highlights continued investor interest in AI-enabled drug development and creates a notable private-market valuation benchmark for healthcare and biotech investors.
Deal terms
raise
Pathos AI
Value
$237M
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- First reported by Pathos AIOct 23Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
- Techmeme reportsOct 23Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025 (Katherine Davis/Axios)
- STAT reportsOct 23STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
- Endpoints News reportsOct 23Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership
Who is involved
STAT+: AI drug firm Pathos raises $237 million, pushing valua…Pathos AItargetTempusBMS
Company
Sources (4)
- Pathos AIOct 23Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
- TechmemeOct 23Pathos AI, which uses AI to develop oncology drugs, raised a $237M Series E at a $3B post-money valuation, up from a $1.6B valuation in May 2025 (Katherine Davis/Axios)
- STATOct 23STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
- Endpoints NewsOct 23Pathos raises $237M at $3B valuation, signs Bristol Myers neuro partnership
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.